Cytokines and cardiac hypertrophy: roles of angiotensin II and basic fibroblast growth factor

D M Kaye1, R A Kelly, T W Smith

  • 1Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.

Insights

Cardiac cells release growth factors like Angiotensin II in response to mechanical stress, driving cardiac hypertrophy. Understanding these molecular mechanisms is key to treating heart muscle growth.

Area of Science:

  • Cardiovascular Biology
  • Molecular Cardiology
  • Cellular Signaling

Background:

  • Hemodynamic factors causing cardiac hypertrophy are known, but cellular mechanisms remain unclear.
  • Trophic factors released by heart cells may influence cardiac growth via autocrine/paracrine signaling.
  • Cardiac myocytes are the primary cells involved in cardiac hypertrophy.

Purpose of the Study:

  • To elucidate the cellular and molecular mechanisms translating mechanical stimuli into cardiac muscle growth.
  • To identify specific trophic factors and signaling pathways involved in cardiac hypertrophy.
  • To investigate the autocrine and paracrine roles of cytokines in cardiac response to mechanical load.

Main Methods:

  • In vivo and in vitro studies examining hypertrophic actions of specific growth factors.
  • Analysis of cytokine release by cardiac myocytes under mechanical load.
  • Investigation of Angiotensin II signaling via the AT(1) receptor subtype.

Main Results:

  • Angiotensin II (via AT(1) receptor), basic fibroblast growth factor, and heparin-binding epidermal growth factor promote cardiac hypertrophy.
  • Cardiac myocytes release these cytokines in response to increased mechanical load.
  • Autocrine and paracrine signaling pathways are implicated in cardiac growth.

Conclusions:

  • Cardiac myocytes release key trophic factors, including Angiotensin II, in response to mechanical stress.
  • These factors mediate cardiac hypertrophy through autocrine and paracrine mechanisms.
  • Understanding these pathways is crucial for developing therapeutic strategies for cardiac hypertrophy.

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cellular Adaptation II: Hypertrophy01:26

Cellular Adaptation II: Hypertrophy

Hypertrophy is the increase in the size of individual cells, resulting in the enlargement of a tissue or organ. Unlike hyperplasia, which involves an increase in cell number, hypertrophy is characterized by an increase in cell volume. This process often occurs in response to higher functional demand or hormonal stimulation, leading to the production of more structural proteins and organelles, thereby enhancing the cells' work capacity.There are two primary types of hypertrophy: physiological...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Role of Hematopoietic Growth Factors01:28

Role of Hematopoietic Growth Factors

Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...